| pubmed-article:2199620 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2199620 | lifeskim:mentions | umls-concept:C1140680 | lld:lifeskim |
| pubmed-article:2199620 | lifeskim:mentions | umls-concept:C0043210 | lld:lifeskim |
| pubmed-article:2199620 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:2199620 | lifeskim:mentions | umls-concept:C0008838 | lld:lifeskim |
| pubmed-article:2199620 | lifeskim:mentions | umls-concept:C0079083 | lld:lifeskim |
| pubmed-article:2199620 | lifeskim:mentions | umls-concept:C1609982 | lld:lifeskim |
| pubmed-article:2199620 | lifeskim:mentions | umls-concept:C1274040 | lld:lifeskim |
| pubmed-article:2199620 | lifeskim:mentions | umls-concept:C0547040 | lld:lifeskim |
| pubmed-article:2199620 | lifeskim:mentions | umls-concept:C0442120 | lld:lifeskim |
| pubmed-article:2199620 | pubmed:issue | 8 | lld:pubmed |
| pubmed-article:2199620 | pubmed:dateCreated | 1990-9-7 | lld:pubmed |
| pubmed-article:2199620 | pubmed:abstractText | From August 1985 to November 1989 we conducted a trial of intraperitoneal (IP) carboplatin including a dose-escalation design in 25 women with advanced gynecologic malignancies. All had extensive prior therapy with cisplatin (median cumulative dose, 525 mg/m2). Carboplatin was administered IP in 2 L of 1.5% dextrose with a 4-hour dwell time every 4 weeks for six cycles at a starting dose of 200 mg/m2. Patients with reduced creatinine clearance (30 to 60 cc/min) were escalated more slowly than those with high (greater than 60 cc/min) clearance. Thrombocytopenia was dose-limiting and often more severe in patients with compromised renal function; there was no local drug toxicity. The median time of follow-up is 25 months. Complete responses (CRs) were documented in six of 23 assessable patients (26%) by repeat laparotomy, and an additional 11 patients (48%) had no disease evident by noninvasive restaging. Five of the CRs and six of the patients with no clinically evident disease have relapsed from 3 to 40 months after therapy. Six patients (26%) are alive and free of disease 8 to 47 (median, 20) months after therapy. IP carboplatin is effective against relapsed ovarian cancer, even after prior cisplatin therapy. | lld:pubmed |
| pubmed-article:2199620 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2199620 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2199620 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2199620 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:2199620 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2199620 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2199620 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2199620 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2199620 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2199620 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2199620 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:2199620 | pubmed:issn | 0732-183X | lld:pubmed |
| pubmed-article:2199620 | pubmed:author | pubmed-author:MuggiaF MFM | lld:pubmed |
| pubmed-article:2199620 | pubmed:author | pubmed-author:GreenMM | lld:pubmed |
| pubmed-article:2199620 | pubmed:author | pubmed-author:CanettiJJ | lld:pubmed |
| pubmed-article:2199620 | pubmed:author | pubmed-author:SoriceGG | lld:pubmed |
| pubmed-article:2199620 | pubmed:author | pubmed-author:HochsterHH | lld:pubmed |
| pubmed-article:2199620 | pubmed:author | pubmed-author:BellerUU | lld:pubmed |
| pubmed-article:2199620 | pubmed:author | pubmed-author:ColomboNN | lld:pubmed |
| pubmed-article:2199620 | pubmed:author | pubmed-author:SpeyerJ LJL | lld:pubmed |
| pubmed-article:2199620 | pubmed:author | pubmed-author:WernzJ CJC | lld:pubmed |
| pubmed-article:2199620 | pubmed:author | pubmed-author:PorgesRR | lld:pubmed |
| pubmed-article:2199620 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2199620 | pubmed:volume | 8 | lld:pubmed |
| pubmed-article:2199620 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2199620 | pubmed:authorsComplete | N | lld:pubmed |
| pubmed-article:2199620 | pubmed:pagination | 1335-41 | lld:pubmed |
| pubmed-article:2199620 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:2199620 | pubmed:meshHeading | pubmed-meshheading:2199620-... | lld:pubmed |
| pubmed-article:2199620 | pubmed:meshHeading | pubmed-meshheading:2199620-... | lld:pubmed |
| pubmed-article:2199620 | pubmed:meshHeading | pubmed-meshheading:2199620-... | lld:pubmed |
| pubmed-article:2199620 | pubmed:meshHeading | pubmed-meshheading:2199620-... | lld:pubmed |
| pubmed-article:2199620 | pubmed:meshHeading | pubmed-meshheading:2199620-... | lld:pubmed |
| pubmed-article:2199620 | pubmed:meshHeading | pubmed-meshheading:2199620-... | lld:pubmed |
| pubmed-article:2199620 | pubmed:meshHeading | pubmed-meshheading:2199620-... | lld:pubmed |
| pubmed-article:2199620 | pubmed:meshHeading | pubmed-meshheading:2199620-... | lld:pubmed |
| pubmed-article:2199620 | pubmed:meshHeading | pubmed-meshheading:2199620-... | lld:pubmed |
| pubmed-article:2199620 | pubmed:meshHeading | pubmed-meshheading:2199620-... | lld:pubmed |
| pubmed-article:2199620 | pubmed:meshHeading | pubmed-meshheading:2199620-... | lld:pubmed |
| pubmed-article:2199620 | pubmed:meshHeading | pubmed-meshheading:2199620-... | lld:pubmed |
| pubmed-article:2199620 | pubmed:meshHeading | pubmed-meshheading:2199620-... | lld:pubmed |
| pubmed-article:2199620 | pubmed:meshHeading | pubmed-meshheading:2199620-... | lld:pubmed |
| pubmed-article:2199620 | pubmed:meshHeading | pubmed-meshheading:2199620-... | lld:pubmed |
| pubmed-article:2199620 | pubmed:meshHeading | pubmed-meshheading:2199620-... | lld:pubmed |
| pubmed-article:2199620 | pubmed:meshHeading | pubmed-meshheading:2199620-... | lld:pubmed |
| pubmed-article:2199620 | pubmed:meshHeading | pubmed-meshheading:2199620-... | lld:pubmed |
| pubmed-article:2199620 | pubmed:meshHeading | pubmed-meshheading:2199620-... | lld:pubmed |
| pubmed-article:2199620 | pubmed:meshHeading | pubmed-meshheading:2199620-... | lld:pubmed |
| pubmed-article:2199620 | pubmed:year | 1990 | lld:pubmed |
| pubmed-article:2199620 | pubmed:articleTitle | Intraperitoneal carboplatin: favorable results in women with minimal residual ovarian cancer after cisplatin therapy. | lld:pubmed |
| pubmed-article:2199620 | pubmed:affiliation | Rita and Stanley H. Kaplan Cancer Center, Department of Medicine, New York University Medical Center. | lld:pubmed |
| pubmed-article:2199620 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:2199620 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:2199620 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2199620 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2199620 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2199620 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2199620 | lld:pubmed |
